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Interaction of doxorubicin DOX with iron and the consequent generation of reactive oxygen species (ROS) is a major player in
DOX-induced cardiomyopathy. Accordingly, this study has been initiated to investigate the preventive eﬀect of the iron chelator,
desferrioxamine (DFX), against DOX-induced acute cardiotoxicity in rats. Male Wistar albino rats were divided into four groups
and were injected intraperitoneally (I.P.) with normal saline, a single dose of DOX (15mg/kg), a single dose of DFX (250mg/kg)
and a combined treatment with DFX (250mg/kg) 30min prior to a single dose of DOX, (15mg/kg). A single dose of DOX signifi-
cantly increased mRNA expression of TGF-β, Smad2, Smad4, CDKN2A and p53 and signiﬁcantly decreased Samd7 and Mdm2
mRNAexpressionlevels.AdministrationofDFXpriortoDOXresultedinacompletereversalofDOX-inducedalterationincardiac
enzymesandgeneexpressiontonormallevels.Datafromthisstudysuggestthat(1)DOXinducesitsacutecardiotoxicitysecondary
to increasing genes expression of TGF-β/Smad pathway. (2) DOX increases apoptosis through upregulation of CDKN2A and p53
and downregulation of Mdm2 gene expression. (3) The preventive eﬀect of DFX against DOX-induced cardiotoxicity is mediated
via the TGF-β1/Smad pathway.
1.Introduction
Doxorubicin (DOX) is a potent anthracycline chemothera-
peutic agent used to treat a wide variety of human malignan-
cies [1]. However, its clinical use is limited by a signiﬁcant
DOX-induced cardiotoxicity which can progress to heart
failure [2–4]. The mechanism by which DOX-induced cardi-
otoxicity has not been fully understood yet; however, several
mechanisms have been proposed. The mechanisms include
increased oxidative stress [5], alteration of myocardial ener-
gy metabolism [6], altered molecular signaling [7], pro-
grammed cell death [4] and iron-dependent oxidative dam-
age to biological macromolecules [8]. One of the mechanism
explained DOX-induced cardiotoxicity is the formation of
free radical-mediated myocytes damage. Iron (Fe) is a crit-
ical biogenic element necessary as oxidation-reduction catal-
ysis and bioenergetics in all living cells. However, this-
metal plays a crucial role in the formation of reactive oxygen
species (ROS) [9]. There are two main pathways by which
Fe may promote ROS formation in DOX-exposed cells, one
of them is the formation of DOX-Fe complexes. The iron
chelator, desferrioxamine (DFX), is used in the treatment of
iron overload status and prevents interaction of DOX with
iron, thus preventing DOX-induced damage in cultured
heart cells [10]. ROS have been proposed as contributing to
the deterioration of cardiac function in patients with both is-
chemic and nonischemic cardiomyopathies [11].
Transforming growth factor-β1( T G F - β1) is formed
mainly by cardiac myoﬁbroblast and ﬁbroblast and is con-
tributed to cardiac ﬁbrosis development, hypertrophy, and
apoptosis [12]. Previous report showed that TGF-β1g e n e
expression is increased in the left ventricular myocardium of
patients with idiopathic hypertrophic cardiomyopathy or di-
latedcardiomyopathyandinanimalsaftermyocardialinfarc-
tion [13]. ROS have been shown to play important roles in
the development of apoptosis under various pathological2 Oxidative Medicine and Cellular Longevity
conditions.OnepotentialmechanismwherebyROSpromote
apoptosis is activating TGF-β [14]. The recombinant human
latent TGF-β was activated in cell free system in the presence
of asbestos and ascorbic acid and that such activation was
reduced signiﬁcantly by addition of superoxide dismutase,
catalase, or DFX [15]. ROS activated TGF-β through two dif-
ferent mechanisms: direct by oxidation of latency association
protein (LAP) and indirectly through activation of matrix
metalloproteinase (MMPs) such as MMP-2 and MMP-9,
which in turn cleave LAP to release active TGF-β [16]. The
activation of latent TGF-β by asbestos-ascorbate mediated
generation of ROS apparently also resulted from oxidative
modiﬁcation in LAP, leading to a loss of its ability to bind
to TGF-β1[ 15]. On the other hand, ROS generated by
ultraviolet light B have been shown to activate TGF-β in
keratinocytes through stimulating MMP-2 and MMP-9 [17].
The initiation of TGF-β/Smad signaling pathway started
by the formation of heteromeric receptor complexes of
speciﬁc type I and II serine/threonine kinases [18, 19]. After
binding of TGF-β to receptor type II, the receptor of type
I is phosphorelated leading to phosphorylation of Smad-2
and -3 then formed a complex with Smad4. This complex
then entered the nucleus and binded to TGF-β respon-
sive gene promoter that regulates their expression [20]. In
addition, the expression of TGF-β1a n dS m a d - 2 ,- 3 ,a n d- 4i s
upregulated during the chronic phase of myocardial infarct
scar healing [21]. Furthermore, Smad proteins are mediators
for the TGF-β-induced apoptosis [22]. Therefore, this study
has been initiated to investigate the preventive eﬀect of the
DFX against DOX-induced cardiotoxicity in rat through
studying genes expression in the TGF-β/Smad pathways.
2.MaterialandMethods
2.1. Animals. Adult male Wistar albino rats, weighing 230–
250gm, were obtained from Animal Care Center, College of
Pharmacy, King Saud University, Riyadh, Saudi Arabia. An-
imals were housed in metabolic cages under controlled envi-
ronmentalconditions (25◦Cand a12hlight/dark cycle).An-
imals had free access to pulverized standard rat pellet diet es-
sentially and tap water. The protocol of this study has been
approved by Research Ethics Committee of the College.
2.2.Materials. Doxorubicin(SandozPharma,Germany)and
desferrioxamine(NOVARTISpharma,Switzerland)wereob-
tained from king Khalled University Hospital drug store.
2.3.ExperimentalDesign. Toachievetheultimate goalofthis
study, a total of 40 adult male Wistar albino rats aged 12
weeks, weighted 230–250 gm were divided randomly into 4
groups of 10 animals each. Animals in the control group
were injected intraperitoneally (I.P.) with normal saline. Rats
in DOX group were injected with a single dose of DOX
(15mg/kg, I.P.). Rats in DFX group were given a single dose
ofDFX(250mg/kg,I.P.).AnimalsinDOX+DFXgroupwere
injected with DFX (250mg/kg) 30min prior to a single dose
of DOX (15mg/kg, I.P.). At 48 hours after the last injection,
animals were anesthetized with ether, and blood samples
were obtained by heart puncture. Part of blood was collected
in nonsilicone coated 4.5mg EDTA tube for complete
blood picture analysis. Sera were separated for measure-
ment of glutamic oxaloacetic transaminase (GOT), lactic
dehydrogenase (LDH), creatine phosphokinase (CK), and
creatine phosphokinase-MB (CK-MB). Heart was excised
and immediately frozen in liquid nitrogen and stored at
−80◦C for RNA extraction.
2.4. Methods
2.4.1. Determination of Serum Cardiotoxicity Enzymatic
Indices. Quantitative determination of GOT, LDH, and CK
levels was measured according to the previous methods
[23–25], respectively. Serum activities of CK isoenzyme
were determined according to the previous published
method [26]. A complete blood picture was measured using
full automatic blood cell counter Model PCE 210N (ERMA
INC, Japan).
2.4.2. Detection ofTGF-β, Smad2, Smad4, Smad7, Cyclin-De-
pendent Kinase Inhibitor 2A (CDKN2A), Murine Dou-
ble Minute (Mdm2), and p53 Gene Expression Level by
Real-Time PCR Using ΔΔCt Method in Heart Tissues
Total RNA Extraction. Total RNA were extracted from frozen
heart tissue by Trizol method according to the manufac-
t u r e r ’ sp r o t o c o la sp r e v i o u s l yd e s c r i b e d[ 27]. RNA quantity
was characterized using a UV spectrophotometer (Nan-
oDrop 8000, thermo scientiﬁc, USA); the isolated RNA has
an A 260/280 ratio of 1.9–2.1. The integrity of RNA was as-
sessed by running an aliquot of the RNA samples on a dena-
turing agarose gel stained with ethidium bromide.
cDNA Synthesis and Real-Time PCR Methods. First-strand
cDNA was synthesized from 1μgo ft o t a lR N Ab yr e v e r s e
transcription with a superscript ﬁrst-strand synthesis system
kit (Invitrogen, CA, USA), according to the manufacturer’s
instructions. Real-time PCR was done according to our
previous study [4] .T h eR a tp r i m e r sa n dp r o b e su s e df o r
quantiﬁcation of β-actin gene, as an internal control, TGF-
β1, Smad2, Smad4, Smad7, CDKN2A, Mdm2, and p53
were designed using Primer Express 3.0 software (Applied
Biosystems, Foster City, CA, USA) and listed in Table 1.
2.4.3. Statistical Analysis. Diﬀerences between obtained val-
ues (mean ± SD, n = 10) were carried out by one-way analy-
sisofvariance(ANOVA)followedbytheTukey-KramerMul-
tiple Comparison Test.aP-valueof0.05orlesswastakenasa
criterion for a statistically signiﬁcant diﬀerence.
3. Results
A signiﬁcant eﬀect of DOX treatment on blood parameter,
and interaction between DOX and DFX were observed in
Table 2. A single dose of DOX treatment resulted in a signifi-
cant decrease in hemoglobin (Hb%) concentration by 25%,Oxidative Medicine and Cellular Longevity 3
Table 1: Primers and probes sequence for TGF-β, Smad2, Smad4, Smad7, CDKN2A, Mdm2, and p53.
Gene Forward primer Reverse primer Probe
TGF-β 5 -TGCCTGACGGTCAGGTCA-3  5 -CAGGAAGGAAGGCTGGAG-3  FAM-CACTATCGGCAATGAGCG-
GTTCCG-TAMRA
Smad7 5 -CCCCATCACCTTAGTCGACTCT-3  5 -GACAGTCTGCAGTTGGTTTGAGA-3  VIC-CCCCTCCTCCTTACTCCAGAT-
ACCCGA-TAMRA
Smad4 5 -ACCAACTTCCCCAACATTCCT-3  5 -ACTATGGCTGCCTGCCAGAA-3 
FAM-
TGGCTTCCACAAGTCAGCCGGC-
TAMRA
Smad2 5 -CCATCCCCGAGAACACTAACTT-3  5 -TGGTGGTCGCTAGTTTCTCCAT-3  VIC-AACCCCAGAGCAATATTCCAG-
AAACCCC-TAMRA
CDKN2A 5 -GGGTCACCGACAGGCATAAC-3  5 -AGTCTCGCGTTGCCAGAAGT-3 
FAM-
TGCTCAAGCACGCCCAGGTGC-
TAMRA
Mdm2 5 -GGTTGTGGGCTGCAGAGAAG-3  5 -TGCAAGGATCAAATGTGTGTCA-3 
HEX-
TCAGCCGGTAAAGGCGCCCACT-
TAMRA,
p53 5 -CACCATGAGCGTTGCTCTGAT-3  5 -GATTTCCTTCCACCCGGATAA-3 
FAM-
ACGGCCTGGCTCCTCCCCAAC-
TAMRA
β-actin 5 -TGCCTGACGGTCAGGTCA-3  5 -CAGGAAGGAAGGCTGGAAG-3  HEX-CACTATCGGCAATGAGCG-
GTTCCG-TAMRA
Table 2: Eﬀect of DOX, DFX, and their combination on blood picture.
Group
Hematological parameters
Hb% RBCs × 106 WBCs × 103 HCT % Platelets × 103
DOX 11.9 ±0.39
∗# 4.9 ±0.30
∗# 3.9 ±0.78
∗# 28.0±1.6
∗# 599 ±44
DFX 16.3 ±0.16 6.7 ±0.16 7.9 ±0.68 39.3 ±1.7 607 ±13
DOX + DFX 12.8 ±0.47 6.6 ±0.56 5.9 ±0.44 36.5 ±2.4 631 ±49
Control 16.0 ±0.22 6.3 ±0.13 7.1 ±0.23 39.8 ±1.5 560 ±41
Eﬀect of DOX, DFX, and their combination on the levels of blood parameter in rats. Data are presented as mean ± SEM (n = 10). ∗ and # indicate signiﬁcant
change from control and their combination, respectively, at P<0.05.
in white blood cells count by 45%, in red blood cells (RBCs)
by 21%, and in hematocrit (HCT%) by 28% compared
to the control group. In the pretreated group with DFX,
there was a complete reversal of the blood parameters that
were decreased in the DOX group compared to the control
level.
Cardiac toxicity induced by DOX was measured by the
changes in enzymatic levels of GOT, LDH, CK, and CK-MB
in serum. Table 3 showed the eﬀect of DOX, DFX pretreat-
ment and their combination on cardiac enzyme levels after
48h of treatment. There was a signiﬁcant increase in the
GOT,LDH,andCKlevelsintheDOXgroupby146%,118%,
and 343%, respectively, compared to the control group.
There was a signiﬁcant increase in CK-MB levels in DOX-
treated group by 92% compared to the control group. Ad-
ministration of desferrioxamine 30 minutes prior to DOX
resulted in complete reversal of DOX-induced increase in
cardiac enzyme to control levels.
The expression levels of TGF-β1, Smad2, Samd4, Smad7,
CDKN2A, Mdm2, and p53 genes are studied in heart tis-
sue, to investigate whether DOX treatment stimulates the
TGF-β1 signaling cascade that leads to cardiac apoptosis.
The eﬀect of DOX and its combination with DFX on TGF-
Table 3: Eﬀect of DOX and DFX on serum cardiac enzyme and
isoenzyme levels in rats.
Group
Serum enzyme level
GOT U/L LDH IU/L CK U/L CK-MB U/L
DOX 118.8 ±6.4
∗# 541.9 ±18
∗# 1312.0 ±67
∗# 325.0 ±104
∗#
DFX 48.5 ±4.7 217.0 ±3.0 298.7 ±15 202.0 ±13
DOX +
DFX 80.4 ±7.8 333.0 ±17 442.2 ±21 210.0 ±64
Control 48.1 ±5.5 249.3 ±13 296.2 ±26 169.0 ±11
Eﬀect of DOX, DFX, and their combination on the serum levels of cardiac
enzyme and isoenzyme levels in rats. Data are presented as mean ± SEM
(n = 10). ∗ and # indicate signiﬁcant change from control and their
combination, respectively, at P<0.05.
β1 expression was shown in Figure 1. A single dose of DOX
resulted in signiﬁcant increase in the gene expression of
TGF-β1 by 5.6-folds and decrease in Smad7 by 0.5-fold
expressions, compared to the control group. On the other
hand, pretreatment with DFX, 30 minuets before DOX
treatment, induced a signiﬁcant repair of the DOX-induced4 Oxidative Medicine and Cellular Longevity
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Figure 1: Eﬀect of DOX, DFX, and their combination on the ex-
pressionlevels of TGF-β (a)andSmad7(b)inrathearttissues.Data
are presented as mean ± SD (n = 10). ∗, # and $ indicate signiﬁcant
change from control, DFX and DOX plus DFX, respectively, at P<
0.05.
alteration in the gene expression of TGF-β1a n dS m ad 7c o m -
pared to the normal expression levels.
Figure 2 shows the eﬀect of DOX, DFX, and their combi-
nation on the gene expression level of Smad2 (a) and Smad4
(b) in rat heart tissue. Treatment with a single dose of
DOX was resulted in signiﬁcant increases in the gene expres-
sion of Smad2 and Smad4 by 3.8- and 4-folds, respectively,
compared to the control group. Interestingly, DFX pretreat-
mentincombinationwithDOXresultedinacompleterever-
salchangeofSmad2and4inducedbyDOXtothenormalex-
pression levels.
Figure 3 shows the eﬀect of DOX, DFX, and their combi-
nation on the gene expression level of CDKN2A (a), Mdm2
(b), and p53 (c) in rat heart tissue. Treatment with DOX re-
sulted in a signiﬁcant decrease by 0.48-fold in Mdm2 and a
signiﬁcant increase by 5.2- and 3.7-folds in the gene expres-
sion of CDKN2 and p53, respectively, compared to the con-
trol group. Also, treatment with DFX 30min prior to DOX
resulted in complete reversal changes of Mdm2, CDKN2A,
and p53 gene expression induced by DOX to the control
levels.
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Figure 2: Eﬀect of DOX, DFX, and their combination on the
expression levels of Smad2 (a) and Smad4 (b) in rat heart tissues.
Data are presented as mean ± SD (n = 10). ∗, # and $
indicate signiﬁcant change from control, DFX and DOX plus DFX,
respectively, at P<0.05.
4. Discussion
In the present study, the possible protective eﬀect of iron
chelator against doxorubicin-induced cardiotoxicity was in-
vestigated. It is well documented that doxorubicin may ex-
ertatleastpartofitscardiotoxicitybyformingDOX-Fecom-
plexesinheartresultinginROSformation.Increaseinserum
LDH, CK, and GOT activity is well known diagnostic marker
formyocardialfunctionastheseenzymesreleasedfromheart
tothebloodstreamleadtoincreasetheirconcentrationinse-
rum [28, 29]. In the current study, single dose of DOX
(15mg/kg) caused a signiﬁcant increase in the serum level of
GOT, LDH, and CK after 48 hours of treatment. The protec-
tive eﬀect of DFX was clearly reﬂected in returning the cardi-
ac enzymes and isoenzymes after combination treatment to
their normal levels. Several reports found similar increases in
the serum cardiac enzyme GOT, LDH, and CK levels follow-
ing the induction of myocardial necrosis in rats [29, 30].
A single dose of DOX resulted in a signiﬁcant decrease in
RBCs and white blood cells (WBCs) counts, HCT% and
Hb% concentration. The decrease in Hb% concentrationOxidative Medicine and Cellular Longevity 5
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Figure 3: Eﬀect of DOX, DFX, and their combination on the expression levels of CDKN2A (a), Mdm2 (b) and p53 (c) in rat heart tissues.
Data are presented as mean ± SD (n = 10). ∗, # and $ indicate signiﬁcant change from control, DFX and DOX plus DFX, respectively, at
P<0.05.
may be associated with decrease in the total content of body
iron as a result of forming DOX-iron complex. Similarly,
PiuraandRabinovichshowedthattreatmentofpatientswith
advanced/recurrent uterine sarcoma with a combination of
DOX and ifosfamide had hematological toxicity represented
in leukopenia in (80%), neutropenia in (80%), thrombocy-
topenia in (20%), and anemia in (20%) of the patients [31].
Oxidative stress is an important contributor to patholog-
ical remodeling, in the failing heart and plays critical role in
cellgrowth,stressresponsesmyocardialremodelingandpro-
grammed cell death [32]. The iron-mediated oxidative stress
is thought to be responsible for DOX cardiotoxicity, but it
is unclear whether it is also required for drug anti-tumor
activity or not. Desferrioxamine acts as an antioxidant
through its ability to decrease the amount of free iron
available for the ROS production through the formation of
DOX-iron complex [33]. The present study demonstrates
that the pretreatment of DFX can prevent the cardiotoxicity
induced by doxorubicin.
TGF-β1genedownregulationleadstosuppressionofmy-
ocardial ﬁbrosis and apoptosis [34]. In the present study,
treated rats with DOX not only express high levels of cardiac
TGF-β1, Smad2, and Smad4 but also exhibit downregulation
in Smad7 gene expression. These ﬁndings suggest the pos-
sible involvement of TGF-β1, Smad2, Smad4, and Smad7
genes in the regulation of cardiotoxicity process.
One of the most commonly mutated genes in human tu-
mors is p53, tumor suppressor gene that controls both cell
cycle arrest and apoptosis in response to DNA damage [35]
The p53 gene regulates the cell cycle by inhibiting the
combination of cyclins with cyclin-dependent kinases. In the
present study, we have explored the mechanism of CDKN2A
and p53 genes as mediators in cardiotoxicity and their roles
inapoptoticinduction.Thecellproliferationiscontrolledvia
a network of extracellular and intracellular cyclin-depend-
ent kinases (CDKs) signaling pathways. Al-Khalaf and his
colleaguesshowedthatCDKinhibitoractsasapoptosismod-
ulator through controlling the expression of transcription
regulators [36]. Our data demonstrate that DOX increased
apoptosis through upregulating CDKN2A and p53 gene
expression.
Mdm2 oncogene is essential to p53 regulation which
bindstoandtherebyinhibitsp53.Therefore,Mdm2geneacts
asaninhibitorforp53functionor,asp53promoterdegrada-
tion by proteasome [37] and in this way, p53 levels are kept
low in normal cells. The participation of Mdm2 in response6 Oxidative Medicine and Cellular Longevity
to DNA damage has been investigated in another study [38].
L´ eveillard and his colleagues investigated the importance of
p53 control in Mdm2 knockout mice in which mice died
early during development but are rescued from death by ad-
ditional deletion of p53 gene [39]. In the current study, there
wasdownregulationofMdm2geneexpressionlevelsinsingle
dose DOX-treated group. Our results showed a decrease in
Mdm2 gene expression level which triggers the apoptotic
process by increasing the p53 gene expression. This clariﬁes
theroleofMdm2incardiotoxicityandalsoshednewlighton
the clinical signiﬁcance of TGF-β/Smad p53 pathway. On the
other hand, the DFX treatment in combination with DOX
leads to downregulation of TGF-β, Smad2 and Smad4 genes
expression as well as upregulation in Smad7 expression that
was associated with a signiﬁcant lowering in cardiac apopto-
sis.
In conclusion data from this study suggest that (1) DOX
induces its acute cardiotoxicity secondary to the increase in
speciﬁc genes expression in TGF-β/Smad pathway. (2) DOX
increases apoptosis through upregulation of CDKN2A and
p53 and downregulation of Mdm2 gene expression. (3) The
preventiveeﬀectofDFXagainstDOX-inducedcardiotoxicity
is mediated via TGF-β1/Smad pathway.
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